Stereotaxis ( (STXS) ) has released its Q1 earnings. Here is a breakdown of the information Stereotaxis presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stereotaxis is a leading company in the surgical robotics sector, specializing in minimally invasive endovascular interventions. In its latest earnings report for the first quarter of 2025, Stereotaxis highlighted key commercial and innovation efforts, including the initial commercialization of its MAGiC system in Europe and the successful demonstration of its GenesisX robot at major global conferences. The company reported a 9% increase in total revenue, reaching $7.5 million, with a notable 29% growth in recurring revenue. However, the company also experienced an operating loss of $5.9 million, attributed to increased operating expenses and non-cash charges. Looking ahead, Stereotaxis maintains a positive outlook, expecting double-digit revenue growth for the full year 2025, driven by strategic product launches and regulatory milestones, setting the stage for substantial growth in 2026.